Compare · MTD vs TLIS
MTD vs TLIS
Side-by-side comparison of Mettler-Toledo International Inc. (MTD) and Talis Biomedical Corporation (TLIS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTD and TLIS operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- MTD carries a market cap of $34.59B.
- MTD has hit the wire 21 times in the past 4 weeks while TLIS has been quiet.
- MTD has more recent analyst coverage (25 ratings vs 5 for TLIS).
- Company
- Mettler-Toledo International Inc.
- Talis Biomedical Corporation
- Price
- -
- -
- Market cap
- $34.59B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1997
- 2021
- News (4w)
- 21
- 0
- Recent ratings
- 25
- 5
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
Talis Biomedical Corporation
Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Latest MTD
- Director Salice Thomas P was granted 77 shares, increasing direct ownership by 26% to 369 units (SEC Form 4)
- Director Zhang Ingrid was granted 54 shares, increasing direct ownership by 26% to 261 units (SEC Form 4)
- Director Wienand Wolfgang was granted 54 shares, increasing direct ownership by 30% to 237 units (SEC Form 4)
- Director Tokich Michael J was granted 54 shares, increasing direct ownership by 108% to 104 units (SEC Form 4)
- Director Shuman-Fabbri Natalia was granted 54 shares, increasing direct ownership by 338% to 70 units (SEC Form 4)
- Director Shepherd Brian A was granted 54 shares, increasing direct ownership by 37% to 200 units (SEC Form 4)
- Director Perversi Pablo was granted 54 shares, increasing direct ownership by 86% to 117 units (SEC Form 4)
- Director Finney Elisha W was granted 54 shares, increasing direct ownership by 14% to 428 units (SEC Form 4)
- Director Doat-Le Bigot Domitille was granted 54 shares, increasing direct ownership by 18% to 349 units (SEC Form 4)
- Director Diggelmann Roland D was granted 138 shares, increasing direct ownership by 19% to 870 units (SEC Form 4)
Latest TLIS
- Amendment: SEC Form SC 13D/A filed by Talis Biomedical Corporation
- SEC Form 15-12G filed by Talis Biomedical Corporation
- SEC Form 25-NSE filed by Talis Biomedical Corporation
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits